When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Axovant Gene Therapies (AXGT) is running three clinical programs on three gene therapy candidates for neurological and developmental disorders. Readouts from all three programs are expected in Q4'19, presenting an opportunity for a trade, which is the focus of this article.
A big Q4'19 upcoming AXGT
AXGT's three clinical programs include a trial of AXO-LENTI-PD, a gene therapy for Parkinson's disease, a trial on AXO-AAV-GM2, a gene therapy for GM2 gangliosidosis and a trial on AXO-AAV-GM1, a gene therapy for GM1 gangliosidosis.
Figure 1: AXGT company pipeline. Source: September corporate presentation.